Virginia / 2026 Regular Session

2026 Regular Session · Imported snapshot

HB1025: Access to investigational drugs, etc.; patient with severely debilitating condition.

failed committee

<b>Access to investigational drugs, biological products, and devices; patient with severely debilitating condition.</b> Allows a patient who has a severely debilitating condition, defined in the bill as a disease or condition that causes major irreversible morbidity, to access investigational drugs, biological products, and devices when certain criteria are met. Under current law, only a patient who has a terminal condition may access such drugs, products, and devices.

Official bill page · Source: Richmond Sunlight

Ask about HB1025

Full bill text

Version HB1025 · 2026-01-14 · Official source text

Full text

Changes in this version: added text deleted text

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3442.1, 54.1-3442.2, and 54.1-3442.3 of the Code of Virginia are amended and reenacted as follows:

§ 54.1-3442.1. Definitions.

As used in this article, unless the context requires a different meaning:

"Investigational drug, biological product, or device" means a drug, biological product, or device that has successfully completed Phase I of a clinical trial but has not been approved for general use by the U.S. Food and Drug Administration and remains under investigation in a clinical trial.

"Severely debilitating condition" means a disease or condition that causes major irreversible morbidity.

"Terminal condition" means a condition caused by injury, disease, or illness from which, to a reasonable degree of medical probability, a patient cannot recover and (i) the patient's death is imminent or (ii) the patient is in a persistent vegetative state.

"Treating physician" means a physician who is providing or has previously provided medical treatment or evaluation to and has or previously had an ongoing treatment relationship with the person.

§ 54.1-3442.2. Eligibility for expanded access to investigational drugs, biological products, and devices; written, informed consent to treatment.

A. A person shall be eligible for expanded access to investigational drugs, biological products, or devices if:

1. He has a terminal or severely debilitating condition, attested to by his treating physician and confirmed by a second physician not previously involved in the treatment of the person who has conducted an independent examination of the person;

2. He has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for him to participate in an ongoing clinical trial for his terminal or severely debilitating condition;

3. The potential benefits of use of the investigational drug, biological product, or device to treat his terminal or severely debilitating condition are greater than the potential risks of the use of the investigational drug, biological product, or device to treat his terminal or severely debilitating condition;

4. He has received a recommendation from his treating physician for use of an investigational drug, biological product, or device for treatment of his terminal or severely debilitating condition; and

5. He or, if he is incapable of making an informed decision, his legally authorized representative has given written informed consent to use of the investigational drug, biological product, or device for treatment of his terminal or severely debilitating condition or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian has given written informed consent to the use of the investigational drug, biological product, or device for treatment of his terminal or severely debilitating condition.

Documentation indicating that the person meets the criteria for eligibility for expanded access to investigational drugs, biological products, or devices shall be provided by the person's treating physician and shall be included in the person's medical record.

B. Written informed consent to use of an investigational drug, biological product, or device shall include:

1. An explanation of the currently approved products and treatments for the person's terminal or severely debilitating condition;

2. A statement that the person has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for the person to participate in an ongoing clinical trial for his terminal or severely debilitating condition;

3. An explanation of the specific investigational drug, biological product, or device proposed for treatment of the person's terminal or severely debilitating condition;

4. A description of possible outcomes resulting from use of the investigational drug, biological product, or device to treat the person's terminal or severely debilitating condition, including a statement that new, unanticipated, different, or worse symptoms might result from and death could be hastened by the proposed treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an awareness of the person's terminal or severely debilitating condition;

5. A statement that the person may be required to pay any costs associated with use of the investigational drug, biological product, or device; and

6. A statement that the person or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian consents to the use of the investigational drug, biological product, or device for treatment of his terminal or severely debilitating condition.

§ 54.1-3442.3. Expanded access to investigational drugs, biological products, or devices; cost; insurance coverage.

A. A manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of § 54.1-3442.2; however, nothing in this article shall require a manufacturer of an investigational drug, biological product, or device to make such investigational drug, biological product, or device available to such person.

B. A manufacturer that makes an investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of § 54.1-3442.2 may provide the investigational drug, biological product, or device to the person free of charge or may require the person to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.

C. An insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services may provide coverage for costs related to treatment of a person's terminal or severely debilitating condition with an investigational drug, biological product, or device; however, nothing in this article shall require an insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services to provide coverage for costs related to treatment of a person's terminal or severely debilitating condition with an investigational drug, biological product, or device.

Legislative actions

2026-01-23 · history

Assigned sub: Health

2026-01-14 · history

Referred to Committee on Health and Human Services

2026-02-18 · history

Left in Committee Health and Human Services

2026-02-05 · history

Fiscal Impact Statement from Department of Planning and Budget (HB1025)

2026-02-10 · history

Subcommittee recommends laying on the table (7-Y 1-N)

2026-02-10 · history

Subcommittee recommends laying on the table

2026-01-14 · history

Prefiled and ordered printed; Offered 01-14-2026 26102452D

Raw source record
{
    "id": 84874,
    "url": "https:\/\/www.richmondsunlight.com\/bill\/2026\/hb1025\/",
    "tags": {
        "149868": "medicine",
        "149869": "healthcare",
        "149870": "drugs",
        "149871": "regulation",
        "149872": "patient rights"
    },
    "text": [
        {
            "date": "2026-01-14",
            "number": "HB1025",
            "pdf_url": "https:\/\/downloads.richmondsunlight.com\/bills\/2026\/hb1025.pdf"
        }
    ],
    "type": "bill",
    "year": 2026,
    "video": null,
    "number": "hb1025",
    "patron": "Walker, Wendell",
    "status": "failed committee",
    "chamber": "house",
    "changes": null,
    "outcome": "failed",
    "related": [
        {
            "id": 84263,
            "name": "Appropriations",
            "year": 2026,
            "count": 3,
            "number": "hb435",
            "status": "failed committee",
            "catch_line": "Palliative Care Info. &amp; Ed. Prog. &amp; Palliative Care &amp; Quality of Life Advisory Council; established.",
            "date_introduced": "January 12, 2026"
        },
        {
            "id": 85075,
            "name": "Commerce and Labor",
            "year": 2026,
            "count": 3,
            "number": "hb1172",
            "status": "failed committee",
            "catch_line": "Pharmacy freedom of choice; specialty pharmacy benefits.",
            "date_introduced": "January 14, 2026"
        },
        {
            "id": 85357,
            "name": "Education and Health",
            "year": 2026,
            "count": 3,
            "number": "sb379",
            "status": "signed by governor",
            "catch_line": "Psilocybin; Board of Pharmacy to reschedule upon federal scheduling changes.",
            "date_introduced": "January 13, 2026"
        },
        {
            "id": 84931,
            "name": "Finance",
            "year": 2026,
            "count": 3,
            "number": "sb271",
            "status": "vetoed by governor",
            "catch_line": "Prescription Drug Affordability Board; established.",
            "date_introduced": "January 12, 2026"
        },
        {
            "id": 85848,
            "name": "Appropriations",
            "year": 2026,
            "count": 3,
            "number": "hb1380",
            "status": "failed committee",
            "catch_line": "Individuals with developmental disabilities; provides to conduct emergency medical drills, etc.",
            "date_introduced": "January 21, 2026"
        }
    ],
    "summary": "<b>Access to investigational drugs, biological products, and devices; patient with severely debilitating condition.<\/b> Allows a patient who has a severely debilitating condition, defined in the bill as a disease or condition that causes major irreversible morbidity, to access investigational drugs, biological products, and devices when certain criteria are met. Under current law, only a patient who has a terminal condition may access such drugs, products, and devices.",
    "version": "HB1025",
    "copatron": [
        {
            "shortname": "wmwilliams",
            "partisanship": 83,
            "name_formatted": "Del. Wren Williams (R-Stuart)"
        }
    ],
    "committee": null,
    "full_text": "<p class=enactstm>Be it enacted by the General Assembly of Virginia:<\/p>\n<p class=enactcls>1. That \u00a7\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.1\/'>54.1-3442.1<\/a>, <a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>, and <a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.3\/'>54.1-3442.3<\/a> of the Code of Virginia are amended and reenacted as follows:<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.1\/'>54.1-3442.1<\/a>. Definitions.<\/p>\n<p class=section>As used in this article, unless the context requires a different meaning:<\/p>\n<p class=section>\"Investigational drug, biological product, or device\" means a drug, biological product, or device that has successfully completed Phase I of a clinical trial but has not been approved for general use by the U.S. Food and Drug Administration and remains under investigation in a clinical trial.<\/p>\n<p class=section><ins>\"Severely debilitating condition\" means <\/ins><ins>a <\/ins><ins>disease<\/ins><ins> or condition<\/ins><ins> that cause<\/ins><ins>s<\/ins><ins> major irreversible morbidity.<\/ins><\/p>\n<p class=section>\"Terminal condition\" means a condition caused by injury, disease, or illness from which, to a reasonable degree of medical probability, a patient cannot recover and (i) the patient's death is imminent or (ii) the patient is in a persistent vegetative state. <\/p>\n<p class=section>\"Treating physician\" means a physician who is providing or has previously provided medical treatment or evaluation to and has or previously had an ongoing treatment relationship with the person.<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>. Eligibility for expanded access to investigational drugs, biological products, and devices; written, informed consent to treatment.<\/p>\n<p class=section>A. A person shall be eligible for expanded access to investigational drugs, biological products, or devices if:<\/p>\n<p class=section>1. He has a terminal<ins> or severely debilitating<\/ins> condition, attested to by his treating physician and confirmed by a second physician not previously involved in the treatment of the person who has conducted an independent examination of the person;<\/p>\n<p class=section>2. He has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for him to participate in an ongoing clinical trial for his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>3. The potential benefits of use of the investigational drug, biological product, or device to treat his terminal<ins> or severely debilitating<\/ins> condition are greater than the potential risks of the use of the investigational drug, biological product, or device to treat his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>4. He has received a recommendation from his treating physician for use of an investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition; and<\/p>\n<p class=section>5. He or, if he is incapable of making an informed decision, his legally authorized representative has given written informed consent to use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian has given written informed consent to the use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition.<\/p>\n<p class=section>Documentation indicating that the person meets the criteria for eligibility for expanded access to investigational drugs, biological products, or devices shall be provided by the person's treating physician and shall be included in the person's medical record.<\/p>\n<p class=section>B. Written informed consent to use of an investigational drug, biological product, or device shall include:<\/p>\n<p class=section>1. An explanation of the currently approved products and treatments for the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>2. A statement that the person has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for the person to participate in an ongoing clinical trial for his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>3. An explanation of the specific investigational drug, biological product, or device proposed for treatment of the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>4. A description of possible outcomes resulting from use of the investigational drug, biological product, or device to treat the person's terminal<ins> or severely debilitating<\/ins> condition, including a statement that new, unanticipated, different, or worse symptoms might result from and death could be hastened by the proposed treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an awareness of the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>5. A statement that the person may be required to pay any costs associated with use of the investigational drug, biological product, or device; and<\/p>\n<p class=section>6. A statement that the person or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian consents to the use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition.<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.3\/'>54.1-3442.3<\/a>. Expanded access to investigational drugs, biological products, or devices; cost; insurance coverage.<\/p>\n<p class=section>A. A manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of \u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>; however, nothing in this article shall require a manufacturer of an investigational drug, biological product, or device to make such investigational drug, biological product, or device available to such person.<\/p>\n<p class=section>B. A manufacturer that makes an investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of \u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a> may provide the investigational drug, biological product, or device to the person free of charge or may require the person to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.<\/p>\n<p class=section>C. An insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services may provide coverage for costs related to treatment of a person's terminal<ins> or severely debilitating<\/ins> condition with an investigational drug, biological product, or device; however, nothing in this article shall require an insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services to provide coverage for costs related to treatment of a person's terminal<ins> or severely debilitating<\/ins> condition with an investigational drug, biological product, or device.<\/p>",
    "catch_line": "Access to investigational drugs, etc.; patient with severely debilitating condition.",
    "duplicates": null,
    "session_id": 32,
    "word_count": 1285,
    "patron_party": "R",
    "patron_place": "Lynchburg",
    "summary_hash": "9dfca9f54aa380095a82e75d574fba59",
    "patron_prefix": "Del.",
    "patron_suffix": "(R-Lynchburg)",
    "status_detail": "failed committee",
    "_rsun_versions": [
        {
            "id": "858e55d711bdbd3e326abb39045cf7a34ec0018b7e9620178deec89b814e7a97",
            "code": "HB1025",
            "bill_id": 84874,
            "source_url": "https:\/\/downloads.richmondsunlight.com\/bills\/2026\/hb1025.pdf",
            "source_date": "2026-01-14",
            "source_hash": "bcbe11029c353d94ad499605f15a903fefc11496bc8f7e4a2c42c74cc4e27e01",
            "source_html": "<p class=enactstm>Be it enacted by the General Assembly of Virginia:<\/p>\n<p class=enactcls>1. That \u00a7\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.1\/'>54.1-3442.1<\/a>, <a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>, and <a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.3\/'>54.1-3442.3<\/a> of the Code of Virginia are amended and reenacted as follows:<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.1\/'>54.1-3442.1<\/a>. Definitions.<\/p>\n<p class=section>As used in this article, unless the context requires a different meaning:<\/p>\n<p class=section>\"Investigational drug, biological product, or device\" means a drug, biological product, or device that has successfully completed Phase I of a clinical trial but has not been approved for general use by the U.S. Food and Drug Administration and remains under investigation in a clinical trial.<\/p>\n<p class=section><ins>\"Severely debilitating condition\" means <\/ins><ins>a <\/ins><ins>disease<\/ins><ins> or condition<\/ins><ins> that cause<\/ins><ins>s<\/ins><ins> major irreversible morbidity.<\/ins><\/p>\n<p class=section>\"Terminal condition\" means a condition caused by injury, disease, or illness from which, to a reasonable degree of medical probability, a patient cannot recover and (i) the patient's death is imminent or (ii) the patient is in a persistent vegetative state. <\/p>\n<p class=section>\"Treating physician\" means a physician who is providing or has previously provided medical treatment or evaluation to and has or previously had an ongoing treatment relationship with the person.<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>. Eligibility for expanded access to investigational drugs, biological products, and devices; written, informed consent to treatment.<\/p>\n<p class=section>A. A person shall be eligible for expanded access to investigational drugs, biological products, or devices if:<\/p>\n<p class=section>1. He has a terminal<ins> or severely debilitating<\/ins> condition, attested to by his treating physician and confirmed by a second physician not previously involved in the treatment of the person who has conducted an independent examination of the person;<\/p>\n<p class=section>2. He has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for him to participate in an ongoing clinical trial for his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>3. The potential benefits of use of the investigational drug, biological product, or device to treat his terminal<ins> or severely debilitating<\/ins> condition are greater than the potential risks of the use of the investigational drug, biological product, or device to treat his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>4. He has received a recommendation from his treating physician for use of an investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition; and<\/p>\n<p class=section>5. He or, if he is incapable of making an informed decision, his legally authorized representative has given written informed consent to use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian has given written informed consent to the use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition.<\/p>\n<p class=section>Documentation indicating that the person meets the criteria for eligibility for expanded access to investigational drugs, biological products, or devices shall be provided by the person's treating physician and shall be included in the person's medical record.<\/p>\n<p class=section>B. Written informed consent to use of an investigational drug, biological product, or device shall include:<\/p>\n<p class=section>1. An explanation of the currently approved products and treatments for the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>2. A statement that the person has, in consultation with his treating physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration and the treating physician has determined that no reasonable opportunity exists for the person to participate in an ongoing clinical trial for his terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>3. An explanation of the specific investigational drug, biological product, or device proposed for treatment of the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>4. A description of possible outcomes resulting from use of the investigational drug, biological product, or device to treat the person's terminal<ins> or severely debilitating<\/ins> condition, including a statement that new, unanticipated, different, or worse symptoms might result from and death could be hastened by the proposed treatment, based on the treating physician's knowledge of the proposed treatment in conjunction with an awareness of the person's terminal<ins> or severely debilitating<\/ins> condition;<\/p>\n<p class=section>5. A statement that the person may be required to pay any costs associated with use of the investigational drug, biological product, or device; and<\/p>\n<p class=section>6. A statement that the person or, if the person is a minor or lacks capacity to provide informed consent, his parent or legal guardian consents to the use of the investigational drug, biological product, or device for treatment of his terminal<ins> or severely debilitating<\/ins> condition.<\/p>\n<p class=catchln>\u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.3\/'>54.1-3442.3<\/a>. Expanded access to investigational drugs, biological products, or devices; cost; insurance coverage.<\/p>\n<p class=section>A. A manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of \u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a>; however, nothing in this article shall require a manufacturer of an investigational drug, biological product, or device to make such investigational drug, biological product, or device available to such person.<\/p>\n<p class=section>B. A manufacturer that makes an investigational drug, biological product, or device available to a person who meets the criteria set forth in subsection A of \u00a7&nbsp;<a href='https:\/\/law.lis.virginia.gov\/vacode\/54.1-3442.2\/'>54.1-3442.2<\/a> may provide the investigational drug, biological product, or device to the person free of charge or may require the person to pay the costs of, or the costs associated with, the manufacture of the investigational drug, biological product, or device.<\/p>\n<p class=section>C. An insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services may provide coverage for costs related to treatment of a person's terminal<ins> or severely debilitating<\/ins> condition with an investigational drug, biological product, or device; however, nothing in this article shall require an insurer proposing to issue individual or group accident and sickness insurance policies providing hospital, medical and surgical, or major medical coverage on an expense-incurred basis, a corporation providing individual or group accident and sickness subscription contracts, or a health maintenance organization providing a health care plan for health care services to provide coverage for costs related to treatment of a person's terminal<ins> or severely debilitating<\/ins> condition with an investigational drug, biological product, or device.<\/p>",
            "source_metadata": {
                "bodyAssociation": "archive-reported-current-version",
                "archiveReference": {
                    "date": "2026-01-14",
                    "number": "HB1025",
                    "pdf_url": "https:\/\/downloads.richmondsunlight.com\/bills\/2026\/hb1025.pdf"
                }
            }
        }
    ],
    "copatron_count": 1,
    "patron_address": [
        "P.O. Box 3331",
        "Lynchburg",
        "VA 24503"
    ],
    "patron_chamber": "house",
    "patron_started": 2020,
    "session_lis_id": 261,
    "status_history": [
        {
            "date": "02\/18\/2026",
            "status": "Left in Committee Health and Human Services",
            "date_raw": "2026-02-18",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "failed committee"
        },
        {
            "date": "02\/10\/2026",
            "status": "Subcommittee recommends laying on the table (7-Y 1-N)",
            "date_raw": "2026-02-10",
            "vote_count": null,
            "lis_vote_id": "296111",
            "translation": "failed subcommittee"
        },
        {
            "date": "02\/10\/2026",
            "status": "Subcommittee recommends laying on the table",
            "date_raw": "2026-02-10",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "failed subcommittee"
        },
        {
            "date": "02\/05\/2026",
            "status": "Fiscal Impact Statement from Department of Planning and Budget (HB1025)",
            "date_raw": "2026-02-05",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": null
        },
        {
            "date": "01\/23\/2026",
            "status": "Assigned sub: Health",
            "date_raw": "2026-01-23",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in subcommittee"
        },
        {
            "date": "01\/14\/2026",
            "status": "Referred to Committee on Health and Human Services",
            "date_raw": "2026-01-14",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "in committee"
        },
        {
            "date": "01\/14\/2026",
            "status": "Prefiled and ordered printed; Offered 01-14-2026 26102452D",
            "date_raw": "2026-01-14",
            "vote_count": null,
            "lis_vote_id": null,
            "translation": "introduced"
        }
    ],
    "chief_patron_id": 447,
    "date_introduced": "2026-01-14",
    "patron_district": 52,
    "patron_shortname": "wswalker",
    "committee_chamber": null,
    "status_detail_date": "02\/18\/2026",
    "committee_shortname": null,
    "patron_name_formatted": "Del. Wendell Walker (R-Lynchburg)"
}